ストックスクリーナーアプリを入手
3.6755
3.10%
0.1105
前日終値:
$3.565
開ける：
$3.65
24時間の取引高:
1,389
Relative Volume:
0.48
時価総額：
$147.37M
収益：
$7.80M
当期純損益:
$-69.02M
株価収益率:
-1.7165
EPS:
-2.1413
ネットキャッシュフロー:
$-66.61M
1週間 パフォーマンス:
-1.99%
1か月 パフォーマンス:
-6.71%
6か月 パフォーマンス:
-24.99%
1年 パフォーマンス:
-36.46%
1日の値動き範囲:
$3.65
$3.65
1週間の範囲:
$3.54
$3.91
52週間の値動き範囲:
$3.36
$7.60
Molecular Partners Ag Adr Stock (MOLN) Company Profile
MOLN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MOLN
Molecular Partners Ag Adr
|
3.65 | 133.30M | 7.80M | -69.02M | -66.61M | -2.1413 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.09 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.51 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.62 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
746.02 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
336.78 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-08-30 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-08-29 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2022-04-27 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2021-07-13 | 開始されました | Cowen | Outperform |
| 2021-07-12 | 再開されました | SVB Leerink | Outperform |
すべてを表示
Molecular Partners Ag Adr (MOLN) 最新ニュース
Leerink Partnrs Issues Positive Outlook for MOLN Earnings - Defense World
EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Molecular Partners Ag shares rise 3.64% intraday after Voyager Therapeutics expands Alzheimer's disease franchise. - AInvest
Molecular Partners (NASDAQ:MOLN) Stock Price Down 3.4% – Should You Sell? - Defense World
Molecular Partners and Orano Med Present Promising Preclinical Data on MP0726, a Radio-DARPin Candidate for Ovarian Cancer Treatment - AInvest
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 - GlobeNewswire Inc.
Molecular Partners shares rise 1.93% after-hours after presenting positive data from ongoing Phase 1/2A trial. - AInvest
Molecular Partners Cuts 40 Jobs, Extends Cash Reach to 2028 - AInvest
Molecular Partners Ag shares rise 6.71% intraday after MIT and Recursion release Boltz-2 AI model. - AInvest
Walmart, Deere, Applied Materials set to report earnings Thursday By Investing.com - Investing.com Nigeria
Walmart, Deere, Applied Materials set to report earnings Thursday - Investing.com
Ziff Davis Inc (NASDAQ:ZD) Shares Jumped 1.54% In A Week. Can It Continue Rising? - Marketing Sentinel
Molecular Partners' AACR 2025 Breakthroughs: Radio-DARPins and Smart T Cell Engagers Ignite Oncology Potential - AInvest
Can Contango ORE, Inc. (CTGO) Climb 163.28% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher - Yahoo Finance
Musk's DOGE Exit Rumors & Weak Q1 Deliveries: How to Play Tesla Now - Yahoo Finance
Why Tractor Supply (TSCO) is a Top Momentum Stock for the Long-Term - Yahoo Finance
TD Cowen maintains Buy on Molecular Partners, target CHF15 - Investing.com India
Molecular Partners reports 2024 annual results - Investing.com India
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet - Yahoo Finance
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero (NASDAQ:MOLN) - Seeking Alpha
US stock market gainers for the last week of April 2022 - Nairametrics
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 - Novartis
Citi Appointed as Depositary Bank for Molecular Partners AG’s ADR Programme - Business Wire
Molecular Partners AG Sponsored ADR (MOLN) - Zacks Investment Research
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19 - Novartis
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 - Novartis
Conference Calls and Individual Investors - MarketBeat
RocheDoing now what patients need next - Roche
Molecular Partners Ag Adr (MOLN) 財務データ
収益
当期純利益
現金流量
EPS
0.23%
大文字化:
|
ボリューム (24 時間):